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The Gram-positive human pathogen Staphylococcus aureus causes a variety of human diseases such as skin in-
fections, pneumonia, and endocarditis. The micrococcal nuclease Nuc1 is one of the major S. aureus virulence
factors and allows the bacterium to avoid neutrophil extracellular trap (NET)–mediated killing. We found that
addition of the protein synthesis inhibitor clindamycin to S. aureus LAC cultures decreased nuc1 transcription
and subsequently blunted nuclease activity in a molecular beacon–based ﬂuorescence assay. We also observed
reduced NET degradation through Nuc1 inhibition translating into increased NET-mediated clearance. Simi-
larly, pooled human immunoglobulin speciﬁcally inhibited nuclease activity in a concentration-dependent
manner. Inhibition of nuclease activity by clindamycin and immunoglobulin enhanced S. aureus clearance
and should be considered in the treatment of S. aureus infections.
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The Gram-positive bacterium Staphylococcus aureus is
a major human pathogen causing a wide spectrum of
diseases, including superﬁcial skin infections as well
as invasive infections, such as bacteremia, endocarditis,
necrotizing fasciitis, and pneumonia [1–3]. Increasing
antibiotic resistance of methicillin-resistant S. aureus
(MRSA), as found in the well-characterized S. aureus
USA 300 LAC strain, renders MRSA strains difﬁcult
to treat and may result in high mortality rates [2, 4].
Vancomycin is used for empiric treatment [5] but dis-
plays various problems, such as slow bactericidal activ-
ity, poor tissue penetration, and no activity against
bacterial virulence factors [6–8]. Moreover, vancomy-
cin-resistant S. aureus strains have developed [9–10].
Thus, additional treatment strategies are necessary to
improve clinical response and to reduce further antibi-
otic resistance development. Ideally, these additive ther-
apeutic strategies should target S. aureus virulence
directly thereby disarming the bacteria and rendering
them more susceptible to host innate immune defenses.
Efﬁcient colonization and avoidance of host defense
after invasion are facilitated by numerous staphylococ-
cal virulence factors, including proteases, lipases, hyal-
uronidase, collagenase, as well as deoxyribonuclease
(nuclease) [11–13]. Two active thermostable nucleases
(Nuc1 and Nuc2), encoded by different open reading
frames, are present in the S. aureus genome [14]. The
nuc1 transcript levels are at their maximum during
the postexponential growth phase, whereas those of
nuc2 are high during the early exponential phase and
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decline afterward [15]. Nuclease activity measurements showed
a strong correlation with the nuc1 transcription levels suggest-
ing Nuc1 to be the major S. aureus nuclease [15]. Furthermore,
a recent study showed that Nuc1 transcription and production
is regulated in vitro and in vivo by the 2-component system
SaeRS [16]. Production of Nuc1 is conserved across methicillin-
susceptible S. aureus and MRSA strains and is therefore used
as a unique marker to distinguish S. aureus from other staph-
ylococcal species [17–18]. It has been shown that the expression
and secretion of nucleases by various bacterial species allows
bacteria to evade killing by the innate immune system through
degradation of neutrophil extracellular traps (NETs) [19–21].
NETs consist of extracellular DNA ﬁbers, histones, antimicro-
bial peptides and cell-speciﬁc proteases designed to entrap and
kill various microbes [22]. In addition to NETs evasion strepto-
coccal nucleases were shown to allow bacteria to circumvent
Toll-like receptor 9–mediated recognition via degradation of
unmethylated CpG-rich bacterial DNA [23].
Various nuclease activity detection methods have been devel-
oped, such as gel electrophoresis, enzyme-linked immunosorbent
assays, or ﬁlter binding. However, they all have some disadvan-
tages, such as being time consuming or discontinuous or requir-
ing handling of radioactive material. To overcome such obstacles,
ﬂuorescence-based assays have been developed using DNA or
RNA target molecules labeled with a ﬂuorophore and a quencher.
In the uncleaved state, the quencher is in spatial proximity to the
ﬂuorophore. On cleavage of the target molecule, the quencher is
no longer in the vicinity of the ﬂuorophore, and an increase in
ﬂuorescence can be measured [24–29].
Owing to its excellent bioavailability, the protein synthesis in-
hibitor clindamycin is commonly used in clinics, in particular
for skin and soft-tissue infections. However, owing to its bacter-
iostatic action, clindamycin is not the treatment of choice for
S. aureus bacteremia. Clindamycin at low concentrations was
shown to inhibit toxic-shock syndrome exotoxin production
[30]. Transcription of most S. aureus exoproteins is consistently
inhibited. Levels of messenger RNA (mRNA) are affected by
protein inhibitors, most likely via inhibition of global regulators
[31]. For example, α-hemolysin expression is impaired by clin-
damycin [32], paralleled by decreased mRNA expression [33].
In addition to antibiotics, immunoglobulin may be used in se-
vere staphylococcal infections as an adjunct treatment. Immu-
noglobulin contains antibodies capable of neutralizing and/or
binding exoproteins of S. aureus [34–35].
We hypothesized that clindamycin as well as immunoglobu-
lin could be used to treat S. aureus infections, aiming to atten-
uate staphylococcal virulence factors and thus rendering the
bacteria more susceptible to host clearance. We present a sim-
ple-to-perform assay to quantify nuclease activity and show that
both clindamycin and immunoglobulin efﬁciently blocked
staphylococcal Nuc1. This translated into more efﬁcient NET-
mediated clearance of S. aureus. Thus, speciﬁc inhibition of
S. aureus nuclease activity should be considered a complemen-
tary treatment strategy for severe staphylococcal infections.
MATERIAL AND METHODS
Bacterial Strains and Growth Conditions
The following bacterial strains were used: S. aureus LAC wild-
type (wt) (CA-MRSA; pulsed-ﬁeld type USA300), nuclease-
deﬁcient derivative LAC Δnuc1 [19, 27], and 3 clinical MRSA
isolates (MRSA 1–3) exhibiting clindamycin resistance with 2
distinct pulse ﬁeld types. All bacterial strains were grown in
Lennox broth (LB) liquid medium (BD Difco) or on blood
agar plates (Trypcase soy agar plus 5% sheep blood; bioMér-
ieux) and incubated with shaking (220 rpm) at 37°C, unless
otherwise indicated. For antibiotic assays, bacterial cultures
were diluted to an optical density at 600 nm (OD600) of 0.1 in
fresh LB and then grown to midlogarithmic phase (OD600, 0.4–
0.5). The cultures were diluted to 3–5 ×105 colony-forming
units/mL, clindamycin hydrochloride (0.03 or 0.6 µg/mL; Ap-
pliChem) or the dilution medium (control) was added, and
the bacteria were grown to postexponential phase (OD600,
2.5 ± 0.1). Bacterial pellets were then frozen in liquid nitrogen,
and bacterial supernatants were harvested and ﬁlter sterilized
(0.22 µm; Millipore Express PES membrane) from bacterial cul-
tures adjusted to an OD600 of 1. Pooled human immunoglobu-
lin (Privigen; CSL Behring) was preincubated with bacterial
supernatants for 30 minutes at 37°C. Immunoglobulin concen-
trations of 25, 10, and 2.5 mg/mL were used, unless otherwise
indicated.
Determination of Minimum Inhibitory Concentration
The minimum inhibitory concentration (MIC) of clindamycin
was determined by using the broth microdilution method, as
described elsewhere [36]. The assay was performed from mid-
logarithmic phase cultures in LB with a standard inoculum of
approximately 3–5 ×105 cells. The MIC of clindamycin for
LAC wt and LAC Δnuc1 was 0.25 mg/L. The clindamycin resis-
tance of the clinical isolates (MRSA 1–3) was tested with the
broth microdilution method as well as a standard E test (Clin-
ical and Laboratory Standards Institute guidelines). The MIC of
MRSA 1–3 was >256 mg/L. All MIC tests with broth microdi-
lution were performed in duplicate and repeated 3 times.
DNA Degradation Assay
To assess nuclease activity, recombinant micrococcal nuclease
(MNase; New England Biolabs) or bacterial supernatants were
incubated with calf thymus DNA (1 mg/mL; Sigma-Aldrich
Chemie) in reaction buffer (5 mmol/L calcium chloride and
50 mmol/LTris-HCl; pH 7.9). After 20 minutes at 37°C, the nu-
clease reaction was stopped by adding 80 mmol/L ethylenedi-
aminetetraacetic acid (pH 8.0; Merck). Next, 10 µL of
each sample was separated on a 0.8% agarose gel (0.5 µg/mL
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ethidium bromide; Sigma-Aldrich Chemie) and visualized with
Gel DOC1000 (Bio-Rad Laboratories) and the IC Capture 2.2
image software (The Imaging Source Europe GmbH).
Quantiﬁcation of DNA Cleavage Using a Molecular Beacon
A 21–base pair imperfect palindrome DNAmolecular beacon (5′
CGA ATT CCT TTT TGG AAT TCG 3′) bearing a HEX ﬂuoro-
phore at the 5′ and a Black Hole Quencher 1 at the 3′ end was
purchased from Microsynth. All reactions were carried out
using the molecular beacon at a concentration of 0.2 µmol/L in
the reaction buffer. Quantitative analysis was started by addition
of nuclease(s) at 37°C and ﬂuorescence (excitation, 530 nm;
emission, 575 nm) was recorded every 15 seconds for 25 minutes.
The background signal was determined and subtracted from the
sample values. The initial digestion rate for the standard was
measured from the slope of the linear portion of the time curve.
Isolation of Human Blood-Derived Neutrophils
Primary human neutrophils were isolated from venous blood
drawn from healthy donors (BD Vacutainer Systems, K2E,
REF 367525) by means of density gradient centrifugation
using the Polymorphprep system according to the manufactur-
er’s protocol (Axis-Shield), as reported elsewhere [37].
Blood was taken from healthy donors in strict accordance
with the institutional guidelines, according to Declaration of
Helsinki principles. The protocol 2010-0126/0 was approved
by the Institutional Review Board of the University of Zurich.
Written informed consent was received from all participants.
Neutrophil Killing Assay
Neutrophils were seeded in ﬂat 96-well tissue culture plates at a
density of 5 × 105 cells per well in Roswell Park Memorial Insti-
tute 1640 medium (PAA Laboratories), containing subinhibitory
concentrations of clindamycin (subclindamycin; 0.03 µg/mL) or
dilution medium as control. For extracellular neutrophil killing
assays, neutrophils were prestimulated with 25 nmol/L phorbol
12-myristate 13-acetate (Sigma-Aldrich Chemie) and the phago-
cytosis inhibitor cytochalasin D (10 µg/mL; MP Biomedicals) for
20 minutes at 37°C with 5% carbon dioxide (CO2). Bacteria
grown overnight in the absence or presence of subclindamycin
were washed with phosphate-buffered saline and adjusted to an
OD600 of 0.4. Bacteria were preincubated for 30 minutes at 37°C
with dilution medium, subclindamycin, or 25 mg/mL immuno-
globulin and then added directly to the neutrophils at a multiplic-
ity of infection of 0.3. After centrifugation, cells were incubated
for 90 minutes at 37°C with 5% CO2. For enumeration of surviv-
ing bacteria (in colony-forming units per milliliter), serial dilu-
tions in sterile water were plated on blood agar plates. Bacterial
growth in the presence of neutrophils was normalized to bacterial
growth under the same conditions in the absence of neutrophils
to make sure that the effect is not due to growth differences of the
strains in the presence or absence of clindamycin.
NET Degradation Assay
To induce extracellular trap formation, neutrophils were seeded
on glass slides (8-mm diameter; Electron Microscopy Sciences)
coated with poly-D-lysine (BD Biosciences) and were then stim-
ulated with 25 nmol/L phorbol 12-myristate 13-acetate for 4
hours at 37°C in a CO2 incubator. Supernatants from bacteria
grown with or without subclindamycin or supernatants preincu-
bated with 25 mg/mL immunoglobulin were diluted (1:20) and
added directly to the NETs. The plates were centrifuged at 538
g for 10 minutes and further incubated for 20 minutes, followed
by ﬁxation with 4% paraformaldehyde (Kantonsapotheke Zu-
rich). After washing and blocking with 2% (wt/vol) bovine
serum albumin (Sigma-Aldrich Chemie) plus 0.2% Triton X-
100 (vol/vol) (Fluka Biochemika) in phosphate-buffered saline
(45 minutes at room temperature), NETs were visualized using
a primary antibody against the histone H2A-H2B-DNA complex
(mouse monoclonal anti-H2A-H2B-DNA; PL2-6; stock 0.9436
mg/mL, diluted 1:1500) [38] or a mouse immunoglobulin G2b
(1.3 mg/mL, diluted 1:2100; Thermo Scientiﬁc) as respective iso-
type control antibody. After overnight incubation at 4°C the slides
were washed and incubated for 45 minutes at room temperature
with the secondary antibody DyLight 488–conjugated goat
anti-mouse immunoglobulinG (1:1000;ThermoScientiﬁc).Extra-
cellular DNA and nuclei were counterstained with 4’, 6-Diamidin-
2-phenylindol (DAPI) dihydrochloride (1:5000; Sigma-Aldrich
Chemie). Microscopic images were obtained at room temperature
with a confocal inverted microscope (CLSM Leica SP5) and a ×20
(multi-immersion NA 0.7) objective at calibrated magniﬁcations.
Images were obtained and processed identically using ImageJ
software (version 1.40g). All image acquisition parameters were
equal. Experiments were performed in duplicate with 3 biological
independent replicates, and ≥3 images captured per slide.
Quantitative Reverse-Transcription Polymerase Chain Reaction
Analysis of nuc1 mRNA
Nuc1 transcripts from LAC wt grown with or without clinda-
mycin to postexponential phase (OD600, 2.5 ± 0.1) were assayed
by means of quantitative reverse-transcription polymerase
chain reaction (qRT-PCR). RNA was isolated with the Ambion
TRI Reagent solution (Invitrogen) according to the manufac-
turer’s protocol. Pellets were lysed with lysing matrix tubes
(0.1 mm silica spheres lysing matrix B; MP Biomedicals) and
the Bead Beater FastPrep Fp120 (Bio 101, Savant) at 6000
rpm for 40 seconds. RNA samples were treated with Ambion
Turbo DNA-free Kit (Invitrogen), according to the manufactur-
er’s protocol. Complementary DNAwas synthesized from 750 ng
of RNA by using an RT enzyme mix (Invitrogen) and 250 ng of
random primers (3 µg/mL; Invitrogen). The qRT-PCR was car-
ried out in 96-well plates (iCycler iQ PC plates; Bio-Rad) using
the SYBR Green ER qPCR Super Mix and a real-time PCR detec-
tion system (iQ5; Bio-Rad Laboratories). Reaction mixtures were
prepared using 250 nmol/L primers (listed in Supplementary
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Table 1) and 1:30 diluted complementary DNA. GyrB and rpoD
were used as housekeeping genes, and the efﬁciency of each prim-
er pair was tested in triplicate. Differences in mRNA levels were
calculated as follows: ΔCt values of gyrB and nuc1 were calculated
by normalization of the mean cycle threshold from each biological
replicate to the median of the biological replicates without clinda-
mycin. For each sample, the fold change was calculated according
to the Pfafﬂ analysis method [39]. PCR experiments were per-
formed using ≥3 biological replicates, each tested in technical
triplicates.
Statistics
For data analyses nonparametric Mann–Whitney U tests, Wil-
coxon signed rank tests, or unpaired 2-tailed Student t tests
were used. P values were calculated with GraphPad Prism soft-
ware (Prism 5; 2007). Differences were considered statistically
signiﬁcant at P < .05.
RESULTS
Quantiﬁcation of Nuclease Activity
To quantify nuclease activity of S. aureus LAC over time, we de-
signed a molecular beacon–based reporter assay. Cleavage of the
molecular beacon by a nuclease resulted in an increase in ﬂuo-
rescence (Supplementary Figure 1A). To test the reliability of
our reporter system and assess its use for quantiﬁcation, the
molecular beacon was incubated with various concentrations
of the commercially available MNase (New England Biolabs).
As depicted in Supplementary Figure 1B, the increase in the
ﬂuorescence signal was proportional to the MNase concentra-
tion with a correlation coefﬁcient of 0.9701.
Inhibition of Extracellular Nuclease (Nuc1) by Clindamycin
S. aureus incubated with subclindamycin has been shown to
alter the expression of the extracellular virulence factors protein
A, α-hemolysin, and serine protease [31]. To investigate its ef-
fects on nuclease activity, LAC wt and LAC Δnuc1 were grown
in the presence or absence of subclindamycin to the postexpo-
nential phase (for viable cell counts, see Supplementary
Figure 2), and extracellular nuclease activity was assessed
using our molecular beacon–based reporter assay. Nuclease ac-
tivity was signiﬁcantly reduced in LAC wt supernatants from
cultures grown in the presence of subclindamycin, compared
with the non–clindamycin-exposed control (P < .01; Student
t test). The strain LAC Δnuc1 showed no detectable nuclease
activity regardless of subclindamycin exposure (Figure 1A).
Nuclease activity was also assessed by visualizing degradation
of calf thymus DNA on an agarose gel. Untreated LAC wt su-
pernatants degraded calf thymus DNA, whereas supernatants of
LAC wt cultures grown with subclindamycin showed only par-
tial degradation. The LAC Δnuc1 supernatant did not show
DNA degradation and was not inﬂuenced by the presence or
absence of subclindamycin (Figure 1B).
Dose-Dependent Inhibition of Nuc1 by Immunoglobulin
Supernatants of LAC wt and LAC Δnuc1 were incubated with-
out or with various concentrations of immunoglobulin. The
molecular beacon–based reporter assay showed that preincuba-
tion with immunoglobulin at a concentration of 25 mg/mL
(P < .01; Student t test) or 10 mg/mL (P < .05; Student t test)
resulted in dose-dependent inhibition of nuclease activity
(Figure 2A). LAC Δnuc1 supernatants displayed no quantiﬁable
nuclease activity regardless of the addition of immunoglobulin.
Figure 1. Quantiﬁcation of Nuc1 activity in Staphylococcus aureus supernatants in the presence or absence of subclindamycin. A, S. aureus cultures
grown to postexponential phase in the presence of subclindamycin resulted in a reduction of nuclease activity. DNA cleavage events were measured as
increase in ﬂuorescence (AU, arbitrary units). Reduced nuclease activity of LAC wild-type (wt) supernatants in the presence of subclindamycin is indicated by
a lower ﬂuorescence signal compared with control without subclindamycin (P < .01 at last measurement time point). Data were pooled from 3 independent
experiments, each performed in triplicate (means ± standard errors of the mean) and statistically analyzed with Student t test. B, Representative agarose gel
of bacterial culture supernatants of LAC wt and LAC Δnuc1 in the presence or absence of subclindamycin after incubation with calf thymus DNA. Nuclease
activity resulted in a smear of degraded DNA; undegraded DNA appeared as a high molecular weight band. Addition of subclindamycin to the LAC wt
cultures resulted in less degraded eukaryotic DNA. Abbreviations: ku, Kunitz units; MNase, micrococcal nuclease; CLI, clindamycin.
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Supernatants were also incubated with calf thymus DNA, and
degradation was analyzed by gel electrophoresis. Immunoglob-
ulin inhibited the nuclease activity in a dose-dependent manner
in LAC wt supernatants (Figure 2B). No nuclease activity
was detected in LAC Δnuc1 supernatants, with or without
immunoglobulin.
Reduced NET Degradation Through Nuc1 Inhibition by
Subclindamycin and Immunoglobulin
S. aureus Nuc1 degrades NETs, thereby evading innate immune
defense [19]. We therefore investigated the inhibitory potential
of subclindamycin and immunoglobulin on nuclease-mediated
NET degradation. NETs were coincubated with bacterial super-
natants from bacteria grown in the presence of subclindamycin,
supernatants preincubated with 25 mg/mL immunoglobulin or
supernatants without clindamycin or immunoglobulin as con-
trols. NETs incubated with supernatants from subclindamycin
showed reduced NET degradation compared with supernatants
from bacteria grown without clindamycin. Reduced NET degra-
dation was also detected when we added supernatants preincu-
bated with immunoglobulin (Figure 3). Supernatants of LAC
Δnuc1 did not show NET degradation.
Enhanced Bacterial Clearance by Neutrophils Due to Reduced
Nuclease Activity
Because our results showed that clindamycin and immuno-
globulin reduced S. aureus extracellular nuclease activity and
subsequent NET degradation, we tested whether addition of
subclindamycin or immunoglobulin would also lead to en-
hanced bacterial clearance in total and in extracellular
neutrophil killing assays. Survival of the LAC Δnuc1 strain
was signiﬁcantly reduced in extracellular neutrophil killing
compared with LAC wt (Figure 4A). In contrast, no differences
in survival were observed between the LAC wt and LAC Δnuc1
strain in total neutrophil killing (Figure 4B). The addition of
subclindamycin and immunoglobulin signiﬁcantly reduced
LAC wt survival in total and extracellular neutrophil killing as-
says (Figure 4A and 4B).
Pharmacological Reduction of Nuclease Activity by
Clindamycin and Reduced nuc1 Transcription
We next investigated whether the reduction of nuclease activity
on exposure to subclindamycin was associated with lower nuc1
expression levels. We performed qRT-PCR on nuc1 of LAC wt
grown in the presence or absence of subclindamycin to postex-
ponential phase. The LAC wt strain grown in the presence of
subclindamycin showed an approximately 7-fold decrease in
nuc1 mRNA transcript compared with the LAC wt strain
grown without subclindamycin (Figure 5).
No Inhibition of Nuclease Activity and nuc1 Transcription by
Clindamycin in Clindamycin-Resistant Strains
Our results showed a regulatory effect of clindamycin on nuc1
expression in our laboratory strain LAC wt. Therefore, we want-
ed to know whether this is also the case for clindamycin-resis-
tant clinical isolates of S. aureus (MRSA 1–3). Quantiﬁcation of
nuclease activity showed no signiﬁcant change on incubation
with 0.03 or 0.6 µg/mL clindamycin in all tested clinical isolates
(Figure 6A). We also performed qRT-PCR on nuc1, and in line
with our nuclease activity data, we did not observe alterations of
Figure 2. Dose-dependent inhibition of Staphylococcus aureus Nuc1 activity by immunoglobulin (IG). Supernatants of LAC wild-type (wt) and LAC
Δnuc1 were preincubated with various amounts of immunoglobulin for 30 minutes at 37°C. A, Nuclease activity in the presence or absence of immuno-
globulin was quantiﬁed with the molecular beacon–based reporter assay. Immunoglobulin dose-dependent inhibition of Nuc1 is shown from ≥3 indepen-
dent experiments (means ± standard errors of the mean). Nuclease activity was signiﬁcantly reduced after preincubation with 25 mg/mL (P < .01) and 10
mg/mL (P < .05) immunoglobulin, compared with control without immunoglobulin. No signiﬁcant reduction in nuclease activity was observed after prein-
cubation with 2.5 mg/mL immunoglobulin. Statistical analysis using Student t test was performed at the last measurement time point. B, Representative
agarose gel of calf thymus DNA after incubation with bacterial culture supernatants of LAC wt and LAC Δnuc1 strains incubated with or without immu-
noglobulin. In the presence of high concentrations of immunoglobulin (25–10 mg/mL), less DNA degradation was observed, suggesting nuclease inhibition.
Abbreviations: AU, arbitrary units; ku, Kunitz units; MNase, micrococcal nuclease.
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nuc1 mRNA levels in our clindamycin-resistant clinical isolates
on incubation with 0.03 or 0.6 µg/mL clindamycin (Figure 6B).
DISCUSSION
Our work shows that addition of immunoglobulin and subclin-
damycin to clindamycin-susceptible MRSA directly blunted
S. aureus nuclease activity, translating into enhanced extra-
cellular clearance of S. aureus by neutrophils. Beneﬁcial effects
were also observed in total neutrophil killing assays, indicating
that subclindamycin and immunoglobulin may affect not only
extracellular nuclease but also other virulence factors.
To treat MRSA infections, the bactericidal cell wall–active an-
tibiotic vancomycin is typically given empirically. However,
persistent bacteremia may be found despite therapeutic vanco-
mycin concentrations in serum [6], illustrating the difﬁculties
Figure 3. Inhibitory effect of subclindamycin and immunoglobulin (IG) on neutrophil extracellular trap (NET) degradation, which was used as an indicator
of nuclease activity. Neutrophils were stimulated with phorbol 12-myristate 13-acetate for NET induction, followed by coincubation with bacterial super-
natants. Reduced nuclease activity translated into reduced NET degradation in the presence of subclindamycin or preincubation with immunoglobulin
(25 mg/mL). Supernatants of LAC Δnuc1 did not show NET degradation. Micrococcal nuclease (MNase; 4 Kunitz units/mL) was used as a positive control
for efﬁcient NET degradation. Representative images are shown. Nuclei were stained with DAPI (blue), and histone-DNA complexes were stained with
AlexaFluor 488–labeled antibody (green). Scale bars represent 100 µm. Abbreviations: CLI, clindamycin; wt, wild type.
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encountered in treating MRSA infections. In addition, antibiot-
ic resistance is increasing [40].
Both clindamycin and immunoglobulin are being used em-
pirically in clinics [41, 42] to treat bacterial infections. In vitro
antagonism of clindamycin and vancomycin against S. aureus
has been described elsewhere [43, 44], but the clinical relevance
of this in vitro antagonism has not yet been prospectively ana-
lyzed. Protein synthesis inhibitors are frequently used owing to
their excellent bioavailability and their ability to overcome the
reduced antibacterial efﬁciency of penicillins on stationary bac-
teria, also known as the Eagle effect [45]. Production of the vir-
ulence factor Panton-Valentine leukocidin was shown to be
down-regulated by the protein synthesis inhibitor linezolid in
a rabbit model of necrotizing pneumonia [46]. In addition to
translational inhibition, sub-MIC protein synthesis inhibitors
were shown to indirectly regulate virulence factors on the tran-
scriptional level [31, 47–49]. Sub-MIC antibiotic levels are com-
mon during infections, owing to reduced perfusion in necrotic
tissue or in abscesses.
S. aureus Nuc1 is one of the most important staphylococcal
virulence factors and plays a key role in evasion of the innate
immune system by facilitating degradation of NETs, promoting
Figure 4. Reduced nuclease activity and enhanced bacterial clearance by neutrophils in the presence of subclindamycin and immunoglobulin. A, In
extracellular neutrophil killing experiments, LAC wild-type (wt) showed signiﬁcantly reduced growth when either treated with subclindamycin or preincu-
bated with 25 mg/mL immunoglobulin, compared with bacteria grown without subclindamycin or immunoglobulin (control). LAC Δnuc1 was not affected by
addition of subclindamycin or immunoglobulin. B, In total neutrophil killing experiments, LAC wt and LAC Δnuc1 grown with subclindamycin or preincubated
with immunoglobulin showed signiﬁcantly reduced growth compared with bacteria without subclindamycin or immunoglobulin (control). No signiﬁcant
difference in relative growth was observed comparing LAC wt and LAC Δnuc1. Data are presented as relative bacterial growth compared with LAC wt
in the presence of neutrophils and absence of clindamycin. Pooled data from 2 independent blood donors (n = 12 in A upper graph; n = 9 in A lower
graph and B upper and lower graph means ± standard errors of the mean), analyzed with the Wilcoxon signed rank test (**P < .01). Abbreviations:
IG, immunoglobulin; CLI, clindamycin; NS, not signiﬁcant.
Figure 5. Down-regulation of Nuc1 transcription in response to subclin-
damycin. Relative transcript levels of nuc1 derived from LAC wild-type (wt)
cultures grown to postexponential phase with and without subclindamycin
were determined by means of quantitative reverse-transcription polymer-
ase chain reaction. Fold change ratios were calculated by normalizing com-
plementary DNA levels of nuc1 against one of the reference genes (gyrB or
rpoD). Data are presented as median fold change of nuc1 gene expression,
and error bars indicate interquartile ranges for each data set. Experiments
were performed with ≥4 independent samples, using the Mann–Whitney
U test; **P < .01. Abbreviation: CLI, clindamycin.
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survival and pathogenicity [19]. To study the effect of protein
synthesis inhibitors or immunoglobulin on nuclease activity,
we designed a sensitive and easy to use high throughput
assay. This assay allowed direct quantiﬁcation of nuclease activ-
ity using a basic real-time PCR machine. This enabled us to in-
vestigate the impact of subclindamycin on Nuc1 activity. We
found that subclindamycin signiﬁcantly lowered the transcrip-
tion of the nuc1 gene and subsequently Nuc1 activity. For
clinicians, this observation defuses concerns that subclindamy-
cin could eventually result in paradoxically boosting viru-
lence factor expression, as was shown for certain virulence
factors of group A streptococci [50]. We also showed that
in the clinical clindamycin-resistant S. aureus strains, sub-
clindamycin did not inhibit Nuc1 expression or nuclease
activity. Because clindamycin neither inhibits bacterial growth
nor attenuates the bacterial virulence factor Nuc1, it will
Figure 6. Effect of clindamycin on nuclease activity and nuc1 transcription in clindamycin-resistant methicillin-resistant Staphylococcus aureus (MRSA)
isolates. A, Clindamycin-resistant S. aureus cultures (MRSA 1, 2, and 3) grown to postexponential phase with 0.03 and 0.6 µg/mL clindamycin did not result
in signiﬁcant alteration of nuclease activity. DNA cleavage events were measured as increase in ﬂuorescence (AU, arbitrary units). Data were pooled from 3
independent experiments, each performed in triplicate (means ± standard errors of the mean). B, Relative transcript levels of nuc1 derived from MRSA 1, 2,
and 3 grown without clindamycin and 0.03 and 0.6 µg/mL clindamycin were determined by means of quantitative reverse-transcription polymerase chain
reaction. Fold change ratios were calculated by normalizing complementary DNA levels of nuc1 against one of the reference genes (gyrB or rpoD). Data are
presented as median fold change of nuc1 gene expression, and error bars indicate interquartile range for each data set. Experiments were performed with
≥3 independent samples. Abbreviation: CLI, clindamycin.
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probably not inﬂuence infections due to clindamycin-resistant
S. aureus.
We have now shown that immunoglobulin reduced S. aureus
nuclease activity and that such inhibition directly translated
into enhanced bacterial clearance. Based on these ﬁndings,
addition of immunoglobulin should be considered as comple-
mentary treatment strategy for severe staphylococcal infections.
Their addition to current state-of-the-art antibacterial treat-
ment, usually consisting of cell wall–active antibiotics such as
vancomycin for MRSA, should help control fulminant S. aureus
infection more efﬁciently. In vivo, however, owing to their large
molecular size, immunoglobulins might not efﬁciently diffuse
toward sites of infection, and they might well be less efﬁcient
than our ﬁndings suggest. Further studies will be required
to address the beneﬁcial effects mediated by immunoglobulin
in vivo.
Taken together, we provide rational evidence supporting and
expanding current treatment concepts of treating S. aureus in-
fections with a cell wall–active antibiotic combined with viru-
lence factor–inhibiting agents, such as protein synthesis
inhibitors or immunoglobulin. Our data also defuse concerns
that subinhibitory concentrations of protein inhibitors might
paradoxically boost virulence factor expression by showing
that subclindamycin efﬁciently blunted Nuc1 in susceptible
S. aureus strains, resulting in enhanced bacterial clearance by
neutrophils.
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